Company: GMRE
Filing Date: 2025-11-14
Form Type: 424B5
Source: 0001104659-25-112543
Chunk: 23

Company: Global Medical REIT Inc.
Filing Date: 2025-11-14
Form: 424B5
Chunk 23
---
 convert such stock into our common stock to the extent that receipt
of shares of our common stock would cause the holder to exceed any of the limitations on ownership and transfer contained in our charter.
In addition, these restrictions could have anti-takeover effects and could reduce the possibility that a third party will attempt to acquire
control of us, which could adversely affect the market price of the Series B Preferred Stock.

<div align='center'>S-13

USE OF PROCEEDS</div>

We estimate that the net proceeds from the sale
of our Series B Preferred Stock in this offering will be approximately $48.1 million (or approximately $55.4 million if the underwriters
exercise their option to purchase additional shares in full), after deducting underwriting discounts and commissions and our estimated
offering expenses.

We intend to contribute the net proceeds of this
offering to our Operating Partnership in exchange for Series B Preferred OP Units in our Operating Partnership. Our Operating Partnership
intends to use the net proceeds from this offering for general corporate purposes, including funding new acquisitions and repaying indebtedness,
which may include amounts outstanding under our Credit Facility.

Our Credit Facility consists of (i) $500
million of term loans, which include (a) a $350 million term loan (“Term Loan A”) and (b) a $150 million term loan
(“Term Loan B”), and (ii) a $400 million revolver (the “Revolver”). Term Loan A is further divided into three
term loans consisting of: (i) $100 million term loan maturing in October 2029, (ii) $100 million term loan maturing in
October 2030; and (iii) $150 million term loan maturing in April 2031. Term Loan B matures in February 2028 and the
Revolver matures in October 2029, with two six-month extension options. Our Credit Facility also includes a $500 million accordion
feature. Amounts repaid under the Revolver may be re-borrowed from time to time, subject to the terms of our Credit Facility.

As of September 30, 2025, we had approximately
$708.5 million in borrowings outstanding under our Credit Facility, net of unamortized debt issuance costs. Interest rates on amounts
outstanding under our Credit Facility equal the term Secured Overnight Financing Rate plus a borrowing spread based on the current pricing
grid in our Credit Facility. Borrowings under our Credit Facility were primarily incurred